Castle Biosciences, Inc. · NASDAQ:CSTL

Castle Biosciences, Inc. financial statements

Castle Biosciences, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue344.2M332.1M219.8M137.0M94.1M62.6M51.9M22.8M13.8M
Cost of revenue71.0M60.2M45.0M32.0M15.8M9.69M7.31M5.30M4.92M
Gross profit273.2M271.9M174.8M105.0M78.3M53.0M44.6M17.5M8.83M
Research and development51.9M52.0M53.6M44.9M29.6M13.3M7.38M4.85M4.47M
Selling, general and administrative229.3M200.0M180.2M143.0M86.7M48.1M29.8M16.5M15.3M
Operating income-42.8M8.67M-68.0M-72.9M-40.1M-6.54M7.33M-3.84M-10.9M
Depreciation and amortization40.8M16.0M12.3M10.5M3.41M472.0K354.0K287.0K310.8K
EBITDA-2.04M24.7M-55.6M-62.3M-36.7M-6.07M7.68M-3.55M-10.6M
Interest expense86.0K577.0K11.0K17.0K1.00K2.63M4.57M2.27M1.65M
Income before tax-29.5M21.6M-57.4M-68.9M-40.0M-10.2M5.35M-6.36M-12.4M
Income tax-5.36M3.32M101.0K-1.77M-8.72M84.0K72.0K9.00K9.73K
Net income-24.2M18.2M-57.5M-67.1M-31.3M-10.3M5.28M-6.37M-12.4M
Earnings per share, basic-0.830.66-2.14-2.58-1.24-0.540.35-5.33-1.26
Earnings per share, diluted-0.830.62-2.14-2.58-1.24-0.54-0.21-5.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents116.7M119.7M98.8M122.9M329.6M409.9M98.8M4.48M1.21M
Short-term investments182.8M173.4M144.3M135.7M000
Receivables43.4M51.2M38.3M23.5M17.3M12.8M14.6M12.1M4.65M
Inventory10.3M8.13M7.94M3.98M2.02M2.22M1.24M882.0K304.6K
Current assets361.1M360.2M295.6M292.3M353.7M429.6M116.7M18.1M6.68M
Property, plant and equipment14.3M9.50M7.10M2.06M1.53M1.47M
Goodwill10.7M10.7M10.7M10.7M000
Total assets578.6M531.2M453.3M447.3M462.6M439.3M119.7M22.4M9.82M
Accounts payable18.7M6.90M10.3M4.73M2.55M2.10M1.86M1.45M1.12M
Current liabilities68.7M49.4M47.7M36.1M24.9M20.9M15.3M6.74M5.22M
Long-term debt9.64M9.74M0019.3M24.5M17.6M
Total debt10.1M10.0M013.4M8.20M026.7M24.5M18.6M
Total liabilities107.7M75.4M62.1M48.2M50.8M23.6M34.6M32.5M24.1M
Shareholders' equity470.9M455.8M391.3M399.1M411.7M415.7M85.1M-56.6M-14.3M
Shares outstanding29.7M28.5M27.4M26.6M25.4M24.8M17.1M1.92M9.78M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations64.3M64.9M-5.63M-41.7M-19.0M9.87M7.01M-12.3M-12.2M
Capital spending-36.0M-28.3M-13.6M-5.63M-3.48M-4.75M-937.0K-277.0K-494.9K
Free cash flow28.3M36.5M-19.2M-47.3M-22.5M5.11M6.08M-12.6M-12.7M
Cash from investing-60.4M-50.1M-16.2M-166.5M-66.7M-4.75M-937.0K-277.0K-494.9K
Cash from financing-6.96M6.14M-2.30M1.51M5.42M305.9M88.3M15.8M8.87M
Dividends paid-1.69M-3.12M00
Share buybacks-5.13M-1.69M-781.0K67.2M10.4M292.7K
Change in cash-2.98M20.9M-24.1M-206.7M-80.2M311.0M94.4M3.27M-3.86M